Historical record - last NADAC effective date: 8/18/2021
Product Information
PIROXICAM 20 MG CAPSULE is a generic product labeled by Unichem Pharmaceuticals (USA) Inc., priced at $0.4615 per EA under NDC 29300025605. Its NADAC has been published 189 times since Jan 10, 2018.
FDA first approved this application on Apr 13, 2017.
The High Outlier badge above means this manufacturer's average price in the Piroxicam market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
20 mg/1
Manufacturer
Unichem Pharmaceuticals (USA) Inc.NDC
29300025605
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
8/18/2021
Active Ingredients
PIROXICAMApproval Type
Generic (ANDA)
FDA Application
ANDA208340FDA Approved
4/13/2017
On Market Since
8/1/2017
Pharmacological Classes
Price Statistics
The NADAC for PIROXICAM 20 MG CAPSULE has been published 189 times since Jan 10, 2018, and over the history we have for it it has declined 54.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4615 per EA |
|---|---|
| All-time high | $1.0113 (Jan 10, 2018) |
| All-time low | $0.3749 (Aug 19, 2020) |
| Median price | $0.5142 |
| Average price | $0.5623 |
| Largest weekly change | +53.6% (May 19, 2021) |
| Weeks tracked | 189 |
| Tracking since | Jan 10, 2018 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
-54.4%
Last surveyed Aug 18, 2021 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 53% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Unichem Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Piroxicam market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PIROXICAM 20 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for PIROXICAM 20 MG CAPSULE, manufactured by Unichem Pharmaceuticals (USA) Inc., is $0.4615 per EA (NDC 29300025605), effective Aug 18, 2021.
How has the price of PIROXICAM 20 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for PIROXICAM 20 MG CAPSULE has declined 54.4%. It has been tracked across 189 weekly CMS publications since Jan 10, 2018.
What are the highest and lowest recorded NADAC prices for PIROXICAM 20 MG CAPSULE?
Since Jan 10, 2018, the NADAC for PIROXICAM 20 MG CAPSULE has ranged from a low of $0.3749 (Aug 19, 2020) to a high of $1.0113 (Jan 10, 2018), with a median of $0.5142 per EA.
Are there cheaper alternatives to PIROXICAM 20 MG CAPSULE?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, PIROXICAM 20 MG CAPSULE, is $0.2147 per EA — about 53% below PIROXICAM 20 MG CAPSULE.
Who manufactures PIROXICAM 20 MG CAPSULE?
PIROXICAM 20 MG CAPSULE (NDC 29300025605) is labeled by Unichem Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.